Immix Biopharma Inc [IMMX] stock is trading at $3.8, up 3.54%. An important factor to consider is whether the stock is rising or falling in short-term value. The IMMX shares have gain 5.26% over the last week, with a monthly amount glided 80.95%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immix Biopharma Inc [IMMX] stock has fluctuated between $1.34 and $4.00 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Immix Biopharma Inc [NASDAQ: IMMX] shares were valued at $3.8 at the most recent close of the market. An investor can expect a potential return of 84.21% based on the average IMMX price forecast.
Analyzing the IMMX fundamentals
Gross Profit Margin for this corporation currently stands at -1.21% with Operating Profit Margin at -246.99%, Pretax Profit Margin comes in at -239.75%, and Net Profit Margin reading is -240.18%. To continue investigating profitability, this company’s Return on Assets is posted at -1.48, Equity is -2.05 and Total Capital is -4.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.65 points at the first support level, and at 3.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.00, and for the 2nd resistance point, it is at 4.20.
Ratios To Look Out For
For context, Immix Biopharma Inc’s Current Ratio is 1.23. On the other hand, the Quick Ratio is 1.23, and the Cash Ratio is 1.16.
Transactions by insiders
Recent insider trading involved Rachman Ilya M, CEO and Chairman, that happened on Sep 17 ’25 when 2500.0 shares were purchased. CFO, Morris Gabriel S completed a deal on Sep 16 ’25 to buy 2600.0 shares. Meanwhile, CEO and Chairman Rachman Ilya M bought 2178.0 shares on Jun 18 ’25.
